SCHEMBL30888669

SCHEMBL30888669

COC(=O)c1cc(O)cc(Cl)c1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 4/20 0.49
▸ CA1 P00915 4/20 0.49
▸ CA2 P00918 4/20 0.49
▸ CA7 P43166 4/20 0.49
▸ CA9 Q16790 4/20 0.49
▸ CA14 Q9ULX7 4/20 0.49
▸ PDK2 Q15119 1/20 0.44
▸ PDK4 Q16654 1/20 0.44
▸ GAA P10253 3/20 0.42
▸ ABL1 P00519 1/20 0.41
▸ PTGS2 P35354 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ MRGPRX4 Q96LA9 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ ACHE P22303 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28023225 0.84 GAA (0.44) CA12CA1CA2CA7CA9
SCHEMBL4509845 0.81 CA12 (0.52) CA12CA1CA2CA7CA9
SCHEMBL29007955 0.81 GAA (0.49) CA12CA1CA2CA7CA9
SCHEMBL30417663 0.81 GAA (0.49) CA12CA1CA2CA7CA9
SCHEMBL8870759 0.81 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL24436888 0.81 CA12 (0.52) CA12CA1CA2CA7CA9
SCHEMBL22492252 0.81 SOS1 (0.43) GAAABL1POLBRECQLMRGPRX4
SCHEMBL30888568 0.80 CYP3A4 (0.53) CA12CA1CA2CA7CA9
SCHEMBL9328510 0.80 GAA (0.47) CA12CA1CA2CA7CA9
SCHEMBL24516637 0.79 GALK1 (0.50) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630403-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 — — EP disclosed
WO-2024121129-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 — — WO disclosed
Send feedback